| Year |
Citation |
Score |
| 2020 |
Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, Hood J, Yang Z, Malik RK, Strum JC, Roberts PJ. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. Journal For Immunotherapy of Cancer. 8. PMID 33004541 DOI: 10.1136/jitc-2020-000847 |
0.316 |
|
| 2020 |
Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. PMID 32130619 DOI: 10.1007/S10549-020-05575-9 |
0.347 |
|
| 2020 |
Bulat I, Maglakelidze M, Murias C, Krastev B, Baird RD, Wardley AM, Roylance R, Crijanovschi A, Gogiladze M, Pritchett Y, McCullough A, Li C, Sorrentino JA, Malik R, Beelen AP. Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P1-19-17 |
0.343 |
|
| 2019 |
Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Gomez MD, Lowczak A, Aljumaily R, Lima CMR, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, ... ... Sorrentino JA, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31504118 DOI: 10.1093/Annonc/Mdz278 |
0.43 |
|
| 2019 |
Liu JY, Souroullas GP, Diekman BO, Krishnamurthy J, Hall BM, Sorrentino JA, Parker JS, Sessions GA, Gudkov AV, Sharpless NE. Cells exhibiting strong promoter activation in vivo display features of senescence. Proceedings of the National Academy of Sciences of the United States of America. PMID 30683717 DOI: 10.1073/Pnas.1818313116 |
0.55 |
|
| 2019 |
O'Shaughnessy J, Wright G, Thummala A, Danso M, Popovic L, Pluard T, Cheung E, Han H, Daniel B, Vojnovic Z, Vasev N, Ling M, Richards D, Wilks S, Milenkovic D, ... Sorrentino J, et al. Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd1-01 |
0.389 |
|
| 2019 |
Dai B, Freed DM, Sorrentino JA, Augustine JJ, Hughes TG, Kang Y, Roberts PJ, Fleming JB, Kim MP. Abstract 4732: CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens Cancer Research. 79: 4732-4732. DOI: 10.1158/1538-7445.Am2019-4732 |
0.402 |
|
| 2019 |
Berz D, Spira A, Gadgeel S, Anderson I, Goldman J, Thompson J, Foster T, Pritchett Y, Cisneros C, Li C, Sorrentino J, Malik R, Beelen A. Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results Annals of Oncology. 30: v631. DOI: 10.1093/Annonc/Mdz260.059 |
0.352 |
|
| 2019 |
Dees E, Aftimos P, van Oordt H, De Vries E, Neven P, Pegram M, Iqbal R, Boers J, Xiao J, Sipes C, Li C, Sorrentino J, Malik R, Beelen A, Menke-van der C. Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC) Annals of Oncology. 30: v121-v122. DOI: 10.1093/Annonc/Mdz242.035 |
0.326 |
|
| 2018 |
Sorrentino JA, Lai A, Weiss JM, Dragnev KH, Owonikoko TK, Adler S, Antal JM, Malik RK, Roberts PJ. Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii598. PMID 32137593 DOI: 10.1093/Annonc/Mdy298.007 |
0.323 |
|
| 2018 |
Bulat I, Maglakelidze M, Murias C, Kurteva GP, Roylance R, Gogiladze M, Crijanovschi A, McCullough A, Shearin E, Sorrentino J, Sipes C, Yang Z, Cai Y, Malik RK, Beelen AP. G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results. Journal of Clinical Oncology. 36: 1061-1061. DOI: 10.1200/Jco.2018.36.15_Suppl.1061 |
0.351 |
|
| 2018 |
Lai AY, Sorrentino JA, Strum JC, Roberts PJ. Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment Cancer Research. 78: 1752-1752. DOI: 10.1158/1538-7445.Am2018-1752 |
0.422 |
|
| 2018 |
Sorrentino JA, Freed DM, Bisi JE, Strum JC, Roberts PJ. Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer Cancer Research. 78: 1522-1522. DOI: 10.1158/1538-7445.Am2018-1522 |
0.395 |
|
| 2018 |
Roberts P, Lai A, Sorrentino J, Malik R. Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Annals of Oncology. 29: iii4. DOI: 10.1093/Annonc/Mdy046.013 |
0.346 |
|
| 2017 |
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, ... Sorrentino JA, et al. CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. Cancer Discovery. PMID 29101163 DOI: 10.1158/2159-8290.Cd-17-0915 |
0.558 |
|
| 2017 |
He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science Translational Medicine. 9. PMID 28446688 DOI: 10.1126/Scitranslmed.Aal3986 |
0.677 |
|
| 2017 |
Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. PMID 28418845 DOI: 10.18632/Oncotarget.16216 |
0.443 |
|
| 2017 |
Wardell SE, Yllanes AP, Baker JG, Baldi RM, Krebs TK, Sorrentino J, Bisi J, Strum J, Norris JD. Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer Cancer Research. 77: 5641-5641. DOI: 10.1158/1538-7445.Am2017-5641 |
0.396 |
|
| 2017 |
Sorrentino JA, Lai AY, Strum JC, Roberts PJ. Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Immunology. 77: 5628-5628. DOI: 10.1158/1538-7445.Am2017-5628 |
0.348 |
|
| 2017 |
Guijarro I, Poteete A, Ferrarotto R, Denning W, Hamdi H, Roberts P, Malik R, Bisi J, Sorrentino J, Strum J, Roarty E, Heymach J. P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth Journal of Thoracic Oncology. 12: S918. DOI: 10.1016/J.Jtho.2016.11.1258 |
0.372 |
|
| 2016 |
Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-induced Myelosuppression. Molecular Cancer Therapeutics. PMID 26826116 DOI: 10.1158/1535-7163.Mct-15-0775 |
0.436 |
|
| 2016 |
Guijarro I, Denning W, Ferrarotto R, Poteete A, Giri U, Bisi JE, Sorrentino JA, Roberts PJ, Strum JC, Malik RK, Roarty E, Heymach J. The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells. Journal of Clinical Oncology. 34: e20099-e20099. DOI: 10.1200/Jco.2016.34.15_Suppl.E20099 |
0.401 |
|
| 2016 |
Sorrentino JA, Bisi JE, Roberts PJ, Strum JC. Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors Cancer Research. 76: 2824-2824. DOI: 10.1158/1538-7445.Am2016-2824 |
0.45 |
|
| 2015 |
Roberts PJ, White HS, Sorrentino JA, Tadema H, Sale M, Tiessen RG, Bisi JE, Makhuli KM, Hoogdalem Ev, Malik RK, Strum JC. Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression. Journal of Clinical Oncology. 33: 2529-2529. DOI: 10.1200/Jco.2015.33.15_Suppl.2529 |
0.356 |
|
| 2015 |
Tiessen RG, Roberts PJ, Sorrentino JA, White HS, Makhuli KM, Bisi JE, Strum JC, Hoogdalem Ev, Malik RK. First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28. Journal of Clinical Oncology. 33: 2527-2527. DOI: 10.1200/Jco.2015.33.15_Suppl.2527 |
0.43 |
|
| 2015 |
Sorrentino JA, He S, Bisi JE, Roberts PJ, Strum JC, Sharpless NE. Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy Cancer Research. 75: 941-941. DOI: 10.1158/1538-7445.Am2015-941 |
0.654 |
|
| 2015 |
Bisi JE, White HS, Sorrentino JA, Roberts PJ, Strum JC. Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies Cancer Research. 75: 1784-1784. DOI: 10.1158/1538-7445.Am2015-1784 |
0.446 |
|
| 2014 |
Sorrentino JA, Sanoff HK, Sharpless NE. Defining the toxicology of aging. Trends in Molecular Medicine. 20: 375-84. PMID 24880613 DOI: 10.1016/J.Molmed.2014.04.004 |
0.508 |
|
| 2014 |
Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, Drobish A, Gordon BB, Alston S, Hurria A, Kleinhans K, et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. Journal of the National Cancer Institute. 106: dju057. PMID 24681605 DOI: 10.1093/Jnci/Dju057 |
0.556 |
|
| 2014 |
Sorrentino JA, Krishnamurthy J, Tilley S, Alb JG, Burd CE, Sharpless NE. p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. The Journal of Clinical Investigation. 124: 169-73. PMID 24334456 DOI: 10.1172/Jci70960 |
0.519 |
|
| 2013 |
Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, Bardeesy N, Castrillon DH, Beach DH, Sharpless NE. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell. 152: 340-51. PMID 23332765 DOI: 10.1016/J.Cell.2012.12.010 |
0.552 |
|
| 2013 |
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats Rna. 19: 141-157. PMID 23249747 DOI: 10.1261/Rna.035667.112 |
0.614 |
|
| 2012 |
Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 21: 751-64. PMID 22698401 DOI: 10.1016/J.Ccr.2012.03.048 |
0.612 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2019 |
O’Shaughnessy J, Wright G, Thummala A, Danso M, Popovic L, Pluard T, Han H, Vojnovic Z, Vasev N, Ma L, Richards D, Wilks S, Milenkovic D, Sorrentino J, Yang Z, et al. Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial Annals of Oncology. 30: v860-v861. DOI: 10.1093/Annonc/Mdz394.011 |
0.289 |
|
| 2022 |
Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, Ozkan-Dagliyan I, Baldelli E, Calvert V, Pierobon M, Sorrentino JA, et al. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. Cancer Research. PMID 36346366 DOI: 10.1158/0008-5472.CAN-22-0391 |
0.289 |
|
| 2021 |
Li C, Hart L, Owonikoko TK, Aljumaily R, Rocha Lima CM, Conkling PR, Webb RT, Jotte RM, Schuster S, Edenfield WJ, Smith DA, Sale M, Roberts PJ, Malik RK, Sorrentino JA. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemotherapy and Pharmacology. PMID 33595690 DOI: 10.1007/s00280-021-04239-9 |
0.263 |
|
| 2020 |
Daniel D, Kuchava V, Bondarenko I, Ivashchuk O, Reddy S, Jaal J, Kudaba I, Hart L, Matitashvili A, Pritchett Y, Morris SR, Sorrentino JA, Antal JM, Goldschmidt J. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. International Journal of Cancer. PMID 33348420 DOI: 10.1002/ijc.33453 |
0.254 |
|
| 2021 |
Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Xiao J, Sorrentino J, et al. Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34887261 DOI: 10.1158/1078-0432.CCR-21-2272 |
0.226 |
|
| 1983 |
Sorrentino JA, Millis AJT, Whipple AP, Colquhoun WR. Lymphoblastoid cell variant in contact-mediated cell spreading Experimental Cell Research. 145: 369-379. PMID 6861900 DOI: 10.1016/0014-4827(83)90015-0 |
0.188 |
|
| 1983 |
Chandrasekhar S, Sorrentino JA, Millis AJ. Interaction of fibronectin with collagen: age-specific defect in the biological activity of human fibroblast fibronectin Proceedings of the National Academy of Sciences of the United States of America. 80: 4747-4751. PMID 6576357 DOI: 10.1073/Pnas.80.15.4747 |
0.175 |
|
| 1984 |
Sorrentino JA, Millis AJT. Structural comparisons of fibronectins isolated from early and late passage cells Mechanisms of Ageing and Development. 28: 83-97. PMID 6513615 DOI: 10.1016/0047-6374(84)90155-6 |
0.135 |
|
| 2011 |
Koturbash I, Scherhag A, Sorrentino J, Sexton K, Bodnar W, Tryndyak V, Latendresse JR, Swenberg JA, Beland FA, Pogribny IP, Rusyn I. Epigenetic alterations in liver of C57BL/6J mice after short-term inhalational exposure to 1,3-butadiene. Environmental Health Perspectives. 119: 635-40. PMID 21147608 DOI: 10.1289/Ehp.1002910 |
0.102 |
|
| 2011 |
Koturbash I, Scherhag A, Sorrentino J, Sexton K, Bodnar W, Swenberg JA, Beland FA, Pardo-Manuel Devillena F, Rusyn I, Pogribny IP. Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. Toxicological Sciences : An Official Journal of the Society of Toxicology. 122: 448-56. PMID 21602187 DOI: 10.1093/Toxsci/Kfr133 |
0.1 |
|
| 1975 |
Sorrentino JA, Whinston AB. The economic implications of recycling exhaustible natural resources: The case for crude oil Ecological Modelling. 1: 219-233. DOI: 10.1016/0304-3800(75)90019-8 |
0.051 |
|
| 2009 |
Meenar MR, Sorrentino JA. Dealing with 3D surface models: Raster and TIN Handbook of Research On Geoinformatics. 73-81. DOI: 10.4018/978-1-59140-995-3.ch010 |
0.049 |
|
| 2006 |
Sorrentino JA. Modelling capillary pressure curves by means of a distribution function Aiche Annual Meeting, Conference Proceedings. |
0.043 |
|
| 1996 |
Bonnet JC, Sorrentino JA. Flooding and holdup in a Scheibel extractor Latin American Applied Research. 26: 227-232. |
0.035 |
|
| 1994 |
Bonnet JC, Sorrentino JA. Holdup measurements in a Scheibel column by means of an ultrasonic technique Journal of Chemical Technology and Biotechnology. 61: 201-207. DOI: 10.1002/jctb.280610304 |
0.032 |
|
| 2014 |
Sorrentino JA, Meenar MR, Lambert AJ, Wargo DT. Housing location in a Philadelphia metro watershed: Can profitable be green? Landscape and Urban Planning. 125: 188-206. DOI: 10.1016/j.landurbplan.2014.02.005 |
0.032 |
|
| 1988 |
Sorrentino JA. Model of social consciousness with applications to personal exchange and energy/environment decisions Mathematical and Computer Modelling. 11: 499-505. DOI: 10.1016/0895-7177(88)90543-2 |
0.031 |
|
| 2008 |
Sorrentino JA, Meenar MMR, Flamm BJ. Suitable housing placement: A gis-based approach Environmental Management. 42: 803-820. PMID 18594901 DOI: 10.1007/s00267-008-9177-4 |
0.031 |
|
| 1993 |
Sorrentino JA. Thermo-hydraulic simulation of a vacuum cooling system Light Metals: Proceedings of Sessions, Tms Annual Meeting (Warrendale, Pennsylvania). 101-103. |
0.03 |
|
| 2004 |
Sorrentino JA, Anlauf H. Prediction of filter-cake properties from particle collective characteristics Fluid - Particle Separations Journal. 16: 135-145. |
0.028 |
|
| 1978 |
Muskin JB, Sorrentino JA. An "effluent" charge approach to aircraft noise abatement Journal of Environmental Economics and Management. 5: 333-350. DOI: 10.1016/0095-0696(78)90018-9 |
0.028 |
|
| 2006 |
Sorrentino JA. From particle collective characteristics to cake permeability: The use of the pore-particle shape factor Aiche Annual Meeting, Conference Proceedings. DOI: 10.1002/ppsc.200601047 |
0.022 |
|
| 2009 |
Meenar MR, Sorrentino JA, Yesmin S. Coupling GPS and GIS Handbook of Research On Geoinformatics. 277-284. DOI: 10.4018/978-1-59140-995-3.ch035 |
0.021 |
|
| 2004 |
Anlauf H, Sorrentino JA. The influence of particle collective characteristics on cake filtration results Chemical Engineering and Technology. 27: 1080-1084. DOI: 10.1002/ceat.200403248 |
0.018 |
|
| 2013 |
Serres H, Sorrentino JA. Utilization of Steam Hoods in Horizontal Table Filters Essential Readings in Light Metals: Alumina and Bauxite, Volume 1. 1: 630-635. DOI: 10.1002/9781118647868.ch87 |
0.018 |
|
| 2013 |
Quintero ID, Sorrentino JA, Rodríguez MA. Deumulsifier-free slop-oil emulsion destabilization American Filtration and Separations Society Spring Conference 2013. 420-432. |
0.011 |
|
| 2003 |
Anlauf H, Sorrentino JA. Influence of Particle Population on Filter Cake Formation and Drying Chemie-Ingenieur-Technik. 75: 1254-1258+1185. DOI: 10.1002/cite.200303248 |
0.01 |
|
| Hide low-probability matches. |